Psychopharmacology and Psychiatry Updates

In this episode, we explore how liver status shapes medication choice for alcohol use disorder. Dr. Kevin Sevarino breaks down a practical algorithm for selecting between naltrexone, acamprosate, disulfiram, and other options, tailored to hepatic function, from early liver disease through decompensated cirrhosis.
Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D.
Host: Richard Seeber, M.D.
Learn more about our memberships here
Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder
Alcohol Use Disorder Algorithm: Medication Selection Based on Liver Status

In this episode, we explore whether GLP-1 agonists like semaglutide can tackle the metabolic toll of antipsychotics in schizophrenia. Can a drug famous for celebrity weight loss actually protect our most vulnerable psychiatric patients from diabetes and obesity before the damage is done?
Faculty: Oliver Freudenreich, M.D., F.A.C.L.P.
Host: Richard Seeber, M.D.
Learn more about our membership here
Earn 0.75 CMEs: Quick Take Vol. 84
GLP-1s in Schizophrenia: Should Semaglutide Be Added for Metabolic Management?

In this episode, we explore three off-label but evidence-supported medications — gabapentin, topiramate, and baclofen — for alcohol use disorder, examining their mechanisms, dosing strategies, tolerability challenges, and which patients are most likely to benefit when first-line treatments have failed.
Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D.
Host: Richard Seeber, M.D.
Learn more about our memberships here
Earn 1.25 CMEs: Pharmacotherapy of Alcohol Use Disorder
Gabapentin, Topiramate, and Baclofen for Alcohol Use Disorder

In this episode, we explore the nuanced landscape of benzodiazepine tapering, guided by a major 2024 joint clinical practice guideline. Are we training a generation of psychiatrists too afraid to prescribe one of psychiatry's most effective drug classes? Dr. Scott Beach unpacks the risks, benefits, and clinical realities.
Faculty: Scott Beach, M.D.
Host: Richard Seeber, M.D.
Learn more about our membership here
Earn 0.75 CMEs: Quick Take Vol. 84
Benzodiazepine Tapering: Key Takeaways From New Guidelines

In this episode, we explore disulfiram (Antabuse), one of the oldest FDA-approved treatments for alcohol use disorder. Dr. Kevin Sevarino breaks down its mechanism, efficacy data, and critical hepatic safety considerations. Could enforced sobriety be the missing piece for your most treatment-resistant patients?
Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D.
Host: Richard Seeber, M.D.
Learn more about our memberships here
Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder
Disulfiram for Alcohol Use Disorder: Mechanisms, Efficacy, and Hepatic Safety Considerations